10.74

2.98% -0.33

Pre-market: 10.75 0.010 +0.09%

CorMedix Inc (CRMD)

Overview News Price History Option Chain Discussions Forecast Stock Split

CorMedix Inc stock is traded at $10.74, with a volume of 2.97M. It is down -2.98% in the last 24 hours and down -2.45% over the past month. CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.

Previous Close:

$11.07

Open:

$11.07

24h Volume:

2.97M

Relative Volume:

2.52

Market Cap:

$673.52M

Revenue:

$65,400

Net Income/Loss:

$-46.34M

P/E Ratio:

-12.49

EPS:

-0.86

Net Cash Flow:

$-38.74M

1W Performance:

-5.37%

1M Performance:

-2.45%

6M Performance:

+112.67%

1Y Performance:

+184.13%

1-Day Range:

$10.60

$11.41

1-Week Range:

$10.16

$11.45

52-Week Range:

$2.89

$13.85

CorMedix Inc Stock (CRMD) Company Profile

Name

CorMedix Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

908-517-9500

Address

400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ

Employee

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

CRMD's Discussions on Twitter

Compare CRMD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRMD	10.74	673.52M	65,400	-46.34M	-38.74M	-0.86
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

CorMedix Inc Stock (CRMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-21	Initiated	Needham	Buy
Sep-29-20	Initiated	JMP Securities	Mkt Outperform
Sep-21-20	Initiated	Truist	Buy
Dec-18-19	Initiated	B. Riley FBR	Buy
Mar-26-19	Reiterated	H.C. Wainwright	Buy
Dec-06-18	Initiated	ROTH Capital	Buy
Sep-25-17	Reiterated	H.C. Wainwright	Buy
Aug-10-17	Reiterated	Rodman & Renshaw	Buy
May-05-17	Reiterated	Rodman & Renshaw	Buy
Nov-11-16	Reiterated	FBR & Co.	Outperform
Mar-17-16	Reiterated	FBR Capital	Outperform
Mar-03-16	Initiated	FBR Capital	Outperform
Nov-16-15	Reiterated	ROTH Capital	Neutral
Oct-29-15	Reiterated	ROTH Capital	Neutral
May-06-15	Downgrade	ROTH Capital	Buy → Neutral
Dec-08-14	Reiterated	ROTH Capital	Buy
Oct-03-11	Downgrade	Maxim Group	Buy → Hold

View All

CorMedix Inc Stock (CRMD) Latest News

Nov 18, 2024

Cormedix EVP Elizabeth Hurlburt sells $1.57m in stock - Investing.com

Nov 18, 2024

When the Price of (CRMD) Talks, People Listen - Stock Traders Daily

Nov 18, 2024

Nov 15, 2024

Nomura Holdings Inc's Strategic Reduction in CorMedix Inc Shares - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns - Simply Wall St

Nov 14, 2024

Nov 08, 2024

CorMedix's SWOT analysis: defencath launch boosts stock outlook By Investing.com - Investing.com Australia

Nov 06, 2024

Nov 04, 2024

CorMedix's SWOT analysis: defencath launch boosts stock outlook - Investing.com India

Nov 04, 2024

Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High? - Yahoo Finance

Nov 04, 2024

CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium - The Manila Times

Nov 04, 2024

Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts - Simply Wall St

Nov 04, 2024

Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic - Yahoo Finance UK

Nov 04, 2024

Nov 01, 2024

CorMedix: Q3 Earnings Snapshot - AOL

Nov 01, 2024

While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate - Yahoo Finance

Nov 01, 2024

Recent 23% pullback isn't enough to hurt long-term CorMedix (NASDAQ:CRMD) shareholders, they're still up 188% over 1 year - Simply Wall St

Nov 01, 2024

Oct 31, 2024

CorMedix Inc. (NASDAQ:CRMD) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 31, 2024

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates - MSN

Oct 31, 2024

CorMedix Inc. Reports Q3 2024 Financial Results - TipRanks

Oct 31, 2024

Oct 30, 2024

CorMedix (CRMD) Q3 2024 Earnings Call Transcript - The Motley Fool

Oct 30, 2024

Earnings call: CorMedix Inc. reports Q3 financials, DefenCath drives growth By Investing.com - Investing.com South Africa

Oct 30, 2024

Earnings call: CorMedix Inc. reports Q3 financials, DefenCath drives growth - Investing.com

Oct 30, 2024

CorMedix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 30, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Oct 30, 2024

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update - The Manila Times

Oct 30, 2024

CorMedix earnings beat by $0.06, revenue topped estimates - Investing.com UK

Oct 30, 2024

Oct 29, 2024

Stellantis N.V. (STLA-N) QuotePress Release - The Globe and Mail

Oct 29, 2024